An update to pain management after spinal cord injury: from pharmacology to circRNAs
Author:
Mazzone Graciela L.1ORCID, Coronel María F.1ORCID, Mladinic Miranda2ORCID, Sámano Cynthia3ORCID
Affiliation:
1. Instituto de Investigaciones en Medicina Traslacional (IIMT) , CONICET-Universidad Austral , Av. Pte. Perón 1500 , B1629AHJ , Pilar , Buenos Aires , Argentina 2. Laboratory for Molecular Neurobiology, Department of Biotechnology , University of Rijeka , 51000 Rijeka , Croatia 3. Departamento de Ciencias Naturales , Universidad Autónoma Metropolitana, Unidad Cuajimalpa . Avenida Vasco de Quiroga 4871 , Col. Santa Fe Cuajimalpa . Alcaldía Cuajimalpa de Morelos , C.P. 05348 , Ciudad de México , México
Abstract
Abstract
Neuropathic pain (NP) following a spinal cord injury (SCI) is often hard to control and therapies should be focused on the physical, psychological, behavioral, social, and environmental factors that may contribute to chronic sensory symptoms. Novel therapeutic treatments for NP management should be based on the combination of pharmacological and nonpharmacological options. Some of them are addressed in this review with a focus on mechanisms and novel treatments. Several reports demonstrated an aberrant expression of non-coding RNAs (ncRNAs) that may represent key regulatory factors with a crucial role in the pathophysiology of NP and as potential diagnostic biomarkers. This review analyses the latest evidence for cellular and molecular mechanisms associated with the role of circular RNAs (circRNAs) in the management of pain after SCI. Advantages in the use of circRNA are their stability (up to 48 h), and specificity as sponges of different miRNAs related to SCI and nerve injury. The present review discusses novel data about deregulated circRNAs (up or downregulated) that sponge miRNAs, and promote cellular and molecular interactions with mRNAs and proteins. This data support the concept that circRNAs could be considered as novel potential therapeutic targets for NP management especially after spinal cord injuries.
Funder
Ministry of Science, Technology and Productive Innovation of Argentina through the Fund for Scientific and Technological Research Departamento de Ciencias Naturales (DCN), de la División de Ciencias Naturales e Ingeniería (DCNI) de la UAM-Cuajimalpa Croatian Science Foundation grant Universidad Austral, CONICET UniRi research IBRO Collaborative Research Grant
Publisher
Walter de Gruyter GmbH
Subject
General Neuroscience
Reference148 articles.
1. Ahuja, C.S., Wilson, J.R., Nori, S., Kotter, M.R.N., Druschel, C., Curt, A., and Fehlings, M.G. (2017). Traumatic spinal cord injury. Nat. Rev. Dis. Prim. 3: 17018, https://doi.org/10.1038/nrdp.2017.18. 2. Bali, K.K. and Kuner, R. (2014). Noncoding RNAs: key molecules in understanding and treating pain. Trends Mol. Med. 20: 437–448, https://doi.org/10.1016/j.molmed.2014.05.006. 3. Berg, M.V.D., Castellote, J.M., Mahillo-Fernandez, I., and de Pedro-Cuesta, J. (2011). Incidence of traumatic spinal cord injury in Aragón, Spain (1972–2008). J. Neurotrauma 28: 469–477, https://doi.org/10.1089/neu.2010.1608. 4. Berta, T., Qadri, Y.J., Chen, G., and Ji, R.R. (2016). Microglial signaling in chronic pain with a special focus on caspase 6, p38 MAP kinase, and sex dependence. J. Dent. Res. 95: 1124–1131, https://doi.org/10.1177/0022034516653604. 5. Bianchi, M.S., Calvo, V., Chasseing, N.A., Lago, N., Libertun, C., Montaner, A.D., and Lux-Lantos, V.A. (2012). Oligodeoxynucleotide IMT504: lack of effect on immune parameters during islet regeneration in single dose streptozotocin-induced diabetes: IMT504, STZ-induced diabetes: IDO, TSG-6. Diabetes Metab. Res. Rev. 28: 156–163, https://doi.org/10.1002/dmrr.1296.
|
|